Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Design Therapeutics (Nasdaq: DSGN) will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York.

Rhea-AI Summary

Design Therapeutics (Nasdaq: DSGN) will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York.

A live webcast and 30-day archive will be available in the investors section of the company’s website.

Argus May 28 session

-3.24% close to close Open Argus

Details

News Market Reaction – DSGN

In the May 28 session, DSGN declined 3.24%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Design Therapeutics’ participation in the 2026 Jefferies Global Healthc...

Analysis

This announcement highlights Design Therapeutics’ participation in the 2026 Jefferies Global Healthcare Conference, offering a platform to reiterate recent RESTORE-FA data and its broader GeneTAC pipeline. Prior quarters featured solid cash levels, with $222.8M reported in Q1 2026 and multiple readouts anticipated from 2026 onward. Investors may focus on how management frames trial progress, regulatory plans, and use of capital, as well as consistency with earlier clinical and financial disclosures.

Key Figures

Conference date: June 4, 2026 Presentation time: 1:25 p.m. ET Webcast archive period: ≥30 days

Conference date

June 4, 2026

Jefferies Global Healthcare Conference fireside chat

Presentation time

1:25 p.m. ET

Scheduled start time of fireside chat

Webcast archive period

≥30 days

Duration webcast will remain available after presentation

Historical Context

5 past events · Latest: May 18

5 events

1. May 18

   Clinical data update

   24h Move

   -25.5%

   Four-week RESTORE-FA DT-216P2 data showing clinical and biomarker improvements.

2. May 17

   Investor webcast

   24h Move

   -25.5%

   Announcement of investor webcast to review RESTORE-FA trial data.

3. Apr 28

   Earnings and updates

   24h Move

   +23.3%

   Q1 2026 results with $222.8M cash and multiple clinical readouts expected.

4. Mar 9

   Earnings and updates

   24h Move

   -3.7%

   FY 2025 results and progress across three GeneTAC clinical programs.

5. Feb 18

   Investor conferences

   24h Move

   -0.9%

   Participation in Oppenheimer and Leerink investor conferences with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York.

A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC^® gene targeted chimera small molecules. The company’s GeneTAC^® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC^® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:
Renee Leck, THRUST
renee@thrustsc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Design Therapeutics (DSGN) present at the 2026 Jefferies Global Healthcare Conference?

Design Therapeutics will participate in a fireside chat on Thursday, June 4, 2026, at 1:25 p.m. ET. According to the company, the event takes place in New York as part of the Jefferies Global Healthcare Conference.

How can investors watch Design Therapeutics' 2026 Jefferies conference fireside chat live?

Investors can watch a live webcast of the fireside chat via a link provided in the investors section of Design Therapeutics' website. According to the company, online access will be available at www.designtx.com.

Will the Design Therapeutics (DSGN) Jefferies 2026 conference webcast be available for replay?

Yes, the webcast of Design Therapeutics’ fireside chat will be archived for at least 30 days. According to the company, the replay will remain accessible in the investors section of its website after the live event.

What type of company is Design Therapeutics (Nasdaq: DSGN)?

Design Therapeutics is described as a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases. According to the company, its pipeline targets high‑need genetic disorders using novel therapeutic approaches.

Where can shareholders find Design Therapeutics' 2026 Jefferies conference details?

Shareholders can find details and the webcast link in the investors section of Design Therapeutics’ website. According to the company, this page will host both the live stream and the archived replay of the fireside chat.